Structure Therapeutics (NASDAQ:GPCR) Given New $70.00 Price Target at HC Wainwright

Structure Therapeutics (NASDAQ:GPCR) had its price target decreased by analysts at HC Wainwright from $100.00 to $70.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s price target points to a potential upside of 68.55% from the stock’s current price.

GPCR has been the topic of several other reports. Leerink Partners reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Wolfe Research initiated coverage on Structure Therapeutics in a report on Thursday, March 26th. They issued a “peer perform” rating on the stock. William Blair reissued an “outperform” rating on shares of Structure Therapeutics in a report on Monday, March 16th. Canaccord Genuity Group initiated coverage on Structure Therapeutics in a report on Monday, April 27th. They issued a “buy” rating and a $101.00 target price on the stock. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a report on Tuesday, April 21st. Three investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $106.75.

Structure Therapeutics Trading Up 0.7%

Structure Therapeutics stock opened at $41.53 on Thursday. The business’s fifty day simple moving average is $43.89 and its two-hundred day simple moving average is $57.21. Structure Therapeutics has a 12 month low of $15.80 and a 12 month high of $94.90. The company has a market capitalization of $2.95 billion, a price-to-earnings ratio of -47.74 and a beta of -1.35.

Structure Therapeutics (NASDAQ:GPCR) last released its earnings results on Thursday, May 7th. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.39) by $0.04. On average, equities research analysts predict that Structure Therapeutics will post -1.64 EPS for the current year.

Institutional Trading of Structure Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Wellington Management Group LLP increased its position in Structure Therapeutics by 25.2% during the fourth quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after acquiring an additional 1,432,797 shares during the last quarter. Avoro Capital Advisors LLC increased its position in Structure Therapeutics by 21.3% during the fourth quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock valued at $455,939,000 after acquiring an additional 1,150,000 shares during the last quarter. Janus Henderson Group PLC increased its position in Structure Therapeutics by 5.2% during the first quarter. Janus Henderson Group PLC now owns 5,354,981 shares of the company’s stock valued at $258,260,000 after acquiring an additional 264,833 shares during the last quarter. BVF Inc. IL increased its position in Structure Therapeutics by 8.6% during the fourth quarter. BVF Inc. IL now owns 3,479,022 shares of the company’s stock valued at $241,966,000 after acquiring an additional 275,105 shares during the last quarter. Finally, Morgan Stanley increased its position in Structure Therapeutics by 261.4% during the fourth quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock valued at $145,209,000 after acquiring an additional 1,510,093 shares during the last quarter. Hedge funds and other institutional investors own 91.78% of the company’s stock.

Structure Therapeutics Company Profile

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.